Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19
Background Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results An observational study of all consecutive adult patients with COVID‐19 admitte...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-12-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.018475 |
| _version_ | 1828888554301816832 |
|---|---|
| author | Omar Saeed Francesco Castagna Ilir Agalliu Xiaonan Xue Snehal R. Patel Yogita Rochlani Rachna Kataria Sasa Vukelic Daniel B. Sims Chikezie Alvarez Mercedes Rivas‐Lasarte Mario J. Garcia Ulrich P. Jorde |
| author_facet | Omar Saeed Francesco Castagna Ilir Agalliu Xiaonan Xue Snehal R. Patel Yogita Rochlani Rachna Kataria Sasa Vukelic Daniel B. Sims Chikezie Alvarez Mercedes Rivas‐Lasarte Mario J. Garcia Ulrich P. Jorde |
| author_sort | Omar Saeed |
| collection | DOAJ |
| description | Background Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years; P<0.01), had lower inflammatory markers (C‐reactive protein, 10.2; interquartile range, 4.5–18.4 versus 12.9; interquartile range, 5.9–21.4 mg/dL; P<0.01) and reduced cumulative in‐hospital mortality (24% versus 39%; P<0.01) than those not on a statin (n=1283). No difference in hospital mortality was noted in patients without diabetes mellitus on or off statin (20% versus 21%; P=0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94; P<0.01) and inverse probability treatment weighting (HR, 0.88; 95% CI, 0.84–0.92; P<0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers. Conclusions Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era. |
| first_indexed | 2024-12-13T12:25:27Z |
| format | Article |
| id | doaj.art-e73d3ce139df450d98538752cf4a55c6 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-13T12:25:27Z |
| publishDate | 2020-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-e73d3ce139df450d98538752cf4a55c62022-12-21T23:46:23ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802020-12-0192410.1161/JAHA.120.018475Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19Omar Saeed0Francesco Castagna1Ilir Agalliu2Xiaonan Xue3Snehal R. Patel4Yogita Rochlani5Rachna Kataria6Sasa Vukelic7Daniel B. Sims8Chikezie Alvarez9Mercedes Rivas‐Lasarte10Mario J. Garcia11Ulrich P. Jorde12Division of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDepartment of Epidemiology and Population Health Albert Einstein College of Medicine New York NYDepartment of Epidemiology and Population Health Albert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYDivision of Cardiology Department of Medicine Montefiore Medical CenterAlbert Einstein College of Medicine New York NYBackground Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years; P<0.01), had lower inflammatory markers (C‐reactive protein, 10.2; interquartile range, 4.5–18.4 versus 12.9; interquartile range, 5.9–21.4 mg/dL; P<0.01) and reduced cumulative in‐hospital mortality (24% versus 39%; P<0.01) than those not on a statin (n=1283). No difference in hospital mortality was noted in patients without diabetes mellitus on or off statin (20% versus 21%; P=0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94; P<0.01) and inverse probability treatment weighting (HR, 0.88; 95% CI, 0.84–0.92; P<0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers. Conclusions Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era.https://www.ahajournals.org/doi/10.1161/JAHA.120.018475COVID‐19diabetes mellitushospitalizationstatin |
| spellingShingle | Omar Saeed Francesco Castagna Ilir Agalliu Xiaonan Xue Snehal R. Patel Yogita Rochlani Rachna Kataria Sasa Vukelic Daniel B. Sims Chikezie Alvarez Mercedes Rivas‐Lasarte Mario J. Garcia Ulrich P. Jorde Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease COVID‐19 diabetes mellitus hospitalization statin |
| title | Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 |
| title_full | Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 |
| title_fullStr | Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 |
| title_full_unstemmed | Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 |
| title_short | Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19 |
| title_sort | statin use and in hospital mortality in patients with diabetes mellitus and covid 19 |
| topic | COVID‐19 diabetes mellitus hospitalization statin |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.120.018475 |
| work_keys_str_mv | AT omarsaeed statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT francescocastagna statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT iliragalliu statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT xiaonanxue statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT snehalrpatel statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT yogitarochlani statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT rachnakataria statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT sasavukelic statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT danielbsims statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT chikeziealvarez statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT mercedesrivaslasarte statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT mariojgarcia statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 AT ulrichpjorde statinuseandinhospitalmortalityinpatientswithdiabetesmellitusandcovid19 |